Friulchem
On 23 July 2019, Friulchem S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 25 July 2019.
Integrae SIM acted as Nomad, Global Coordinator, Private Placement Bookrunner, and Specialist of the Issuer.
The total equivalent of the resources raised through the operation amounts to Euro 4.5 million, through the issuance of 2,499,750 newly issued shares without nominal value.
The placement price The unit price of the shares resulting from the placement was set at Euro 1.80; based on this price, the market capitalization at the beginning of the negotiations was equal to Euro 14.4 million.
The enterprise. Friulchem (AIM: FCM), active for over 20 years on the market, is today one of the main Italian CDMOs (Contract Development Manufacturing Organizations) active internationally in healthcare through the research and development and production on behalf of third parties of semi-finished and finished products containing both pharmaceutical active ingredients and food supplements, with particular specialization in so-called drug delivery systems for the veterinary sector that represents Friulchem’s excellence, and in the development of dossiers for generic drugs for the human sector. Friulchem is an innovative SME and B2B company with an appreciable propensity for the end client to have solid Italian roots thanks to the production plant in Vivaro (Pordenone) and the administrative headquarters in Milan. The Company, strongly oriented to R&D, boasts consolidated relationships with the main multinationals in the pharmaceutical sector.
Ultima Ricerca Friulchem
BREAKING NEWS| In the press release dated August 7, 2025, Litix SpA, an Innovative SME that combines art, technology, tradition, and innovation through three business units offering solutions ranging from the design and production of robotic cells for marble and other materials, to the creation of sculptures and other artistic and design works, to hardware and software development for additive manufacturing and other advanced processes, announced that its subsidiary Aivox Srl will take part, as an industrial partner, in the national research project “More4Neuro – Multi-material 3D Printing for Education in Neurosurgery.” The initiative, led by the University of Milan within the framework of the Partenariati Estesi – HealthTech program, aims to develop next-generation simulators for medical and neurosurgical training, capable of accurately replicating the tactile, mechanical, and structural properties of brain tissues through multimaterial additive manufacturing technologies. Aivox, specialized in computational design, software development, additive manufacturing, and multimaterial 3D printing, will contribute its expertise by taking responsibility for the design of physical models, definition of production processes, and validation of prototypes through iterative development and clinical testing phases. The activities assigned to Aivox have a total value of € 0.68 million, of which € 0.54 million will be covered by public funding. This project marks another step in the strategy outlined in the latest annual report, in which Litix emphasized the importance of diversifying its portfolio with highly innovative projects and strengthening its position in advanced technology markets, based on the belief that technological development and global presence are the key growth drivers in the medium term. Following a transitional year in 2024, which marked the first full year of Aivox’s operations, the participation in More4Neuro confirms the Group’s ability to seize opportunities in high-potential sectors, expanding the intersection between digital manufacturing and specialized education. Considering the information disclosed in the press release, we confirm our recommendation: Target Price € 2.50, BUY Rating and MEDIUM Risk. |
